Cheung, Phyllis F.
Yang, JiaJin
Fang, Rui
Borgers, Arianna
Krengel, Kirsten
Stoffel, Anne
Althoff, Kristina
Yip, Chi Wai http://orcid.org/0000-0003-3327-5695
Siu, Elaine H. L.
Ng, Linda W. C.
Lang, Karl S.
Cham, Lamin B.
Engel, Daniel R.
Soun, Camille
Cima, Igor http://orcid.org/0000-0002-6196-6971
Scheffler, Björn
Striefler, Jana K.
Sinn, Marianne
Bahra, Marcus
Pelzer, Uwe http://orcid.org/0000-0001-9213-2737
Oettle, Helmut
Markus, Peter
Smeets, Esther M. M.
Aarntzen, Erik H. J. G.
Savvatakis, Konstantinos
Liffers, Sven-Thorsten
Lueong, Smiths S.
Neander, Christian
Bazarna, Anna
Zhang, Xin
Paschen, Annette
Crawford, Howard C.
Chan, Anthony W. H.
Cheung, Siu Tim http://orcid.org/0000-0003-2147-315X
Siveke, Jens T. http://orcid.org/0000-0002-8772-4778
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CH 2320/2-3, SI1549/3-1)
Ministry of Education, Culture, Sports, Science and Technology
Wilhelm Sander-Stiftung (2017.148.1, 2017.148.1)
Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (05160556)
Deutsche Krebshilfe (70112505)
Article History
Received: 7 March 2021
Accepted: 22 October 2021
First Online: 10 January 2022
Competing interests
: J.T.S. reports the following disclosures: Bristol Myers Squibb, Celgene, Roche (Research Funding); AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in iTheranostics and Pharma15 (<3%); member of the Board of Directors for Pharma15, all outside the submitted work. The other authors declare no competing interests.